MENU
Showcases Stock ranks Forex

Geron Corp (GERN)
3.73  0.05 (1.36%) 04-18 16:00
Open: 3.71 Pre. Close: 3.68
High: 3.87 Low: 3.6403
Volume: 9,734,638 Market Cap: 2,193(M)
Stock Technical Analysis
Overall:     
Target: Six months: 4.73
One year: 5.53
Support: Support1: 2.63
Support2: 1.75
Resistance: Resistance1: 4.05
Resistance2: 4.73
Pivot: 3.42
Moving Averages: MA(5): 3.62
MA(20): 3.39
MA(100): 2.36
MA(250): 2.51
MACD: MACD(12,26): 0.28
Signal(12,26,9): 0.28
%K %D: %K(14,3): 61.33
%D(3): 54.67
RSI: RSI(14): 67.10
52-Week: High: 4.05
Low: 1.64
Change(%): 48.6
Average Vol(K): 3-Month: 12914
10-Days: 11643
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 3.876 - 3.891 3.891 - 3.908
Low: 3.603 - 3.619 3.619 - 3.635
Close: 3.704 - 3.732 3.732 - 3.76
Price, MAs and Bollinger Bands
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.

[ GERN ] has closed below upper band by 13.2%. Bollinger Bands are 21.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
Company profile
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.
Stock chart
Stock News
Thu, 18 Apr 2024
Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

Wed, 17 Apr 2024
Geron (NASDAQ:GERN) Stock Price Up 4.7% - MarketBeat

Mon, 15 Apr 2024
Geron Co. (NASDAQ:GERN) Short Interest Down 8.4% in March - MarketBeat

Thu, 11 Apr 2024
Geron Corporation (NASDAQ:GERN) Is Expected To Breakeven In The Near Future - Yahoo Finance

Fri, 15 Mar 2024
Geron (GERN) Gets ODAC Votes for Blood Disorder Drug, Shares Up - Zacks Investment Research

Fri, 15 Mar 2024
Geron’s stock soars 95% after FDA panel votes in favor of blood-disorder drug - MarketWatch

Financial Analysis
Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Underperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Exchange:  NASDAQ Global Select
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M)
Shares Float (M) 588.06
% Held by Insiders 475070016.00
% Held by Institutions 0.09
Shares Short (K) 44910
Shares Short Prior Month (K)
Stock Financials
EPS -193500000.000
Book Value (p.s.)
Profit Margin
Operating Margin -236.00
Return on Assets (ttm) 39.1
Return on Equity (ttm) -41.5
Qtrly Rev. Growth 237000.0
Gross Profit (p.s.) -127.377
Sales Per Share -184.082
EBITDA (p.s.)
Qtrly Earnings Growth -0.32
Operating Cash Flow (M)
Levered Free Cash Flow (M) -167.74
Stock Valuation
PE Ratio
PEG Ratio -2.28
Price to Book value
Price to Sales -0.02
Price to Cash Flow 4.95
Stock Dividends
Dividend
Dividend Yield
Dividend Growth 46660000.000

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android